DK1937252T3 - Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration - Google Patents

Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration

Info

Publication number: DK1937252T3
Authority: DK; Denmark
Prior art keywords: inhibition; compositions; neuronal degeneration; stimulating neurogenesis; neurogenesis
Prior art date: 2005-09-19

Application number

DK06803851.2T

Other languages

English (en)

Inventor

Andersson Judith Kelleher

Original Assignee

Neuronascent Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-19

Filing date

2006-09-19

Publication date

2017-11-20

2006-09-19 Application filed by Neuronascent Inc filed Critical Neuronascent Inc

2017-11-20 Application granted granted Critical

2017-11-20 Publication of DK1937252T3 publication Critical patent/DK1937252T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK06803851.2T 2005-09-19 2006-09-19 Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration DK1937252T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US71869105P	2005-09-19	2005-09-19
US82220206P	2006-08-11	2006-08-11
PCT/US2006/036463 WO2007035722A2 (en)	2005-09-19	2006-09-19	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration

Publications (1)

Publication Number	Publication Date
DK1937252T3 true DK1937252T3 (da)	2017-11-20

Family

ID=37889462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06803851.2T DK1937252T3 (da)	2005-09-19	2006-09-19	Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration

Country Status (12)

Country	Link
US (3)	US8039462B2 (da)
EP (1)	EP1937252B1 (da)
JP (1)	JP5554496B2 (da)
KR (2)	KR101132378B1 (da)
CN (3)	CN106474118A (da)
AU (1)	AU2006292256B2 (da)
CA (2)	CA2623507C (da)
DK (1)	DK1937252T3 (da)
IL (3)	IL190179A (da)
PL (1)	PL1937252T3 (da)
RU (1)	RU2440346C2 (da)
WO (1)	WO2007035722A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2623507C (en) *	2005-09-19	2013-03-12	Neuronascent, Inc.	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CA2774558A1 (en) *	2009-09-22	2011-03-31	Neuronascent, Inc.	Methods and pharmaceutical compositions for treating down syndrome
CA2754237A1 (en) *	2011-05-27	2012-11-27	The Regents Of The University Of California	Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
DK2822558T3 (da) *	2012-03-06	2020-03-23	The Board Of Trustees Of The Univ Of Illionis	Procaspase 3 aktivering ved hjælp af kombinations terapi
JP6231691B2 (ja) *	2013-09-12	2017-11-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	インドール−カルボキサミド誘導体
RU2630654C2 (ru) *	2015-07-29	2017-09-11	Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта)	Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
RU2670128C2 (ru) *	2016-12-16	2018-10-18	Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта)	Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов
KR20190081386A (ko)	2017-12-29	2019-07-09	강원대학교산학협력단	루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081385A (ko)	2017-12-29	2019-07-09	강원대학교산학협력단	옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
AU2022289728A1 (en) *	2021-06-11	2023-11-16	Neuronascent, Inc.	Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3571489A (en) *	1966-12-23	1971-03-16	Max Levy & Co Inc	Transparent substrate having graded optical density conductors thereon
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3612745A (en) *	1970-07-08	1971-10-12	Sierracin Corp	Flexural bus bar assembly
US4057671A (en) *	1975-06-27	1977-11-08	Ppg Industries, Inc.	Heated laminated window and method of assembling same
US4089809A (en) *	1976-03-01	1978-05-16	The United States Of America As Represented By The United States Department Of Energy	Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) *	1978-04-26	1980-11-18	Alessi Anthony A	Notching tool
ATE8584T1 (de) *	1980-01-16	1984-08-15	Hans Georg Prof. Dr. Weder	Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
US4361751A (en) *	1980-07-24	1982-11-30	Ppg Industries, Inc.	Electroconductive window having improved bus bar
US4323726A (en) *	1980-07-24	1982-04-06	Ppg Industries, Inc.	Electrical bus bar assembly
GR79603B (da) *	1982-07-24	1984-10-31	Pfizer
US4485054A (en) *	1982-10-04	1984-11-27	Lipoderm Pharmaceuticals Limited	Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en) *	1982-11-12	1984-03-20	American Cyanamid Company	Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4540786A (en) *	1983-08-22	1985-09-10	The Dow Chemical Company	Preparation of 2-chloro-3-cyano-quinolines
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4532089A (en) *	1984-01-14	1985-07-30	Northwestern University	Method of preparing giant size liposomes
US4897269A (en) *	1984-09-24	1990-01-30	Mezei Associates Limited	Administration of drugs with multiphase liposomal delivery system
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
US5580575A (en) *	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
GB9425986D0 (en) *	1994-12-22	1995-02-22	Pilkington Glass Ltd	Electrically heated window
US5820880A (en) *	1995-06-07	1998-10-13	The United States Of America As Represented By The Secretary Of The Army	Liposomal formulation
US5665428A (en) *	1995-10-25	1997-09-09	Macromed, Inc.	Preparation of peptide containing biodegradable microspheres by melt process
US5736152A (en) *	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
US6287588B1 (en) *	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
PL360581A1 (en) *	1999-05-11	2004-09-06	Ortho-Mcneil Pharmaceutical, Inc.	Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
WO2002016360A2 (en) *	2000-08-18	2002-02-28	Cor Therapeutics, Inc.	Nitrogenous heterocyclic compounds
US6974818B2 (en) *	2002-03-01	2005-12-13	Euro-Celtique S.A.	1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
EP1534681A1 (en) *	2002-06-27	2005-06-01	Schering Aktiengesellschaft	Substituted quinoline ccr5 receptor antagonists
US8013156B2 (en) *	2003-03-19	2011-09-06	Exelixis, Inc.	Tie-2 modulators and methods of use
EP1631992A2 (en) *	2003-06-12	2006-03-08	Patterning Technologies Limited	Transparent conducting structures and methods of production thereof
CA2623507C (en) *	2005-09-19	2013-03-12	Neuronascent, Inc.	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration

2006
- 2006-09-19 CA CA2623507A patent/CA2623507C/en active Active
- 2006-09-19 RU RU2008109821/04A patent/RU2440346C2/ru active
- 2006-09-19 CN CN201610900496.7A patent/CN106474118A/zh active Pending
- 2006-09-19 PL PL06803851T patent/PL1937252T3/pl unknown
- 2006-09-19 CN CN201210246309.XA patent/CN102743382B/zh active Active
- 2006-09-19 CN CN2006800414246A patent/CN101304743B/zh active Active
- 2006-09-19 AU AU2006292256A patent/AU2006292256B2/en active Active
- 2006-09-19 WO PCT/US2006/036463 patent/WO2007035722A2/en active Application Filing
- 2006-09-19 KR KR1020087009255A patent/KR101132378B1/ko active IP Right Grant
- 2006-09-19 US US12/066,640 patent/US8039462B2/en active Active
- 2006-09-19 JP JP2008531431A patent/JP5554496B2/ja active Active
- 2006-09-19 CA CA2800945A patent/CA2800945C/en active Active
- 2006-09-19 DK DK06803851.2T patent/DK1937252T3/da active
- 2006-09-19 EP EP06803851.2A patent/EP1937252B1/en active Active
- 2006-09-19 KR KR1020117015480A patent/KR101158568B1/ko active IP Right Grant
2008
- 2008-03-16 IL IL190179A patent/IL190179A/en active IP Right Grant
2011
- 2011-09-13 US US13/231,584 patent/US8999972B2/en active Active
2014
- 2014-02-04 IL IL230807A patent/IL230807B/en not_active IP Right Cessation
2015
- 2015-04-06 US US14/679,874 patent/US9539261B2/en active Active
2017
- 2017-12-21 IL IL256489A patent/IL256489A/en unknown

Also Published As

Publication number	Publication date
RU2440346C2 (ru)	2012-01-20
RU2008109821A (ru)	2009-10-27
US8999972B2 (en)	2015-04-07
CA2800945C (en)	2017-12-05
CA2623507A1 (en)	2007-03-29
IL190179A (en)	2014-02-27
IL190179A0 (en)	2008-11-03
IL230807A0 (en)	2014-03-31
US8039462B2 (en)	2011-10-18
JP5554496B2 (ja)	2014-07-23
AU2006292256B2 (en)	2013-05-02
WO2007035722A2 (en)	2007-03-29
CA2623507C (en)	2013-03-12
CN101304743B (zh)	2012-09-05
US9539261B2 (en)	2017-01-10
US20110319391A1 (en)	2011-12-29
PL1937252T3 (pl)	2018-01-31
JP2009508876A (ja)	2009-03-05
KR20080065616A (ko)	2008-07-14
US20080234253A1 (en)	2008-09-25
WO2007035722A8 (en)	2007-11-29
CA2800945A1 (en)	2007-03-29
EP1937252A4 (en)	2010-07-28
KR101158568B1 (ko)	2012-07-02
CN102743382B (zh)	2016-12-07
IL230807B (en)	2018-01-31
US20150209371A1 (en)	2015-07-30
IL256489A (en)	2018-02-28
KR20110084556A (ko)	2011-07-25
KR101132378B1 (ko)	2012-04-03
AU2006292256A1 (en)	2007-03-29
WO2007035722A3 (en)	2007-07-19
CN102743382A (zh)	2012-10-24
CN106474118A (zh)	2017-03-08
WO2007035722B1 (en)	2008-02-07
EP1937252B1 (en)	2017-10-25
CN101304743A (zh)	2008-11-12
EP1937252A2 (en)	2008-07-02

Publication	Publication Date	Title
DK1937252T3 (da)	2017-11-20	Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration
DK2155188T3 (da)	2013-11-04	Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK1858864T3 (da)	2012-09-10	Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK2796469T3 (da)	2019-08-12	Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK1888033T3 (da)	2014-05-26	Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK2101819T3 (da)	2013-04-29	Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK1830838T3 (da)	2013-01-21	Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1917246T3 (da)	2010-03-29	Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1969391T3 (da)	2014-10-27	Tyndfilm emitter-absorber indretning og fremgangsmåde
DK1896077T3 (da)	2012-12-03	Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK1791791T3 (da)	2019-08-26	Fremgangsmåder og sammensætninger til behandling af vand
DK3081215T3 (da)	2020-04-27	Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
SG137989A1 (en)	2008-01-28	Compositions and methods for inhibition of the JAK pathway
DK1858488T4 (da)	2022-09-12	Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf
DK1877232T3 (da)	2014-08-11	Fremgangsmåde til behandling af træoverflader
DK2137537T3 (da)	2013-07-29	Sammensætninger og anvendelser til behandling af multipel sklerose
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK2187880T3 (da)	2014-03-10	Sammensætninger og fremgangsmåder til behandling af makuladegeneration
DK2001611T3 (da)	2021-12-13	Fremgangsmåde og sammensætning til oprensning af jord
DK2220116T3 (da)	2012-11-26	Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
IL251169A0 (en)	2017-04-30	Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones
DK3095447T3 (da)	2022-01-31	Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
DK2069467T3 (da)	2014-10-20	Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2063881T3 (da)	2019-08-12	Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
DK2043671T3 (da)	2020-06-15	Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber